24/7 Market News Weekly Wrap 25 Jan 2024
DENVER, Colo., Jan. 25, 2024 (247marketnews.com)- 24/7 Market News covered the following companies today; LAVA Therapeutics NV (NASDAQ:LVTX), Processa Pharmaceuticals (NASDAQ:PCSA), and Rail Vision Ltd. (NASDAQ:RVSN).
News of LAVA Therapeutics (NASDAQ:LVTX) entering into a clinical trial collaboration and supply agreement with Merck & Co., to evaluate its anti-PD-1 therapy KEYTRUDA (pembrolizumab) in combination with LAVA-1207, in patients with therapy refractory metastatic castration-resistant prostate cancer, had it humming in the premarket.
We covered LAVA Therapeutics when it was trading at $1.89, up $0.34 (+21.94%), on 1.46M shares traded. It ran to $2.74 in the premarket, on 17.3M premarket shares, but the volume slowed in the regular trading session, where it topped out at $2.43.
For more information, visit www.lavatherapeutics.com.
Processa Pharmaceuticals (NASDAQ:PCSA) reported the successful completion of its safety tolerability evaluation in its Phase 1b trial of Next Generation Capecitabine and that “NGC-Cap was better tolerated with positive preliminary efficacy results than FDA-approved capecitabine.” Additionally, two dosage regimens have been selected for the Phase 2 trial, from the Phase 1b data, which will be in advanced or metastatic breast cancer given FDA’s agreement that the Phase 1b data can be used to support the design of the Phase 2 trial in breast cancer.
We covered Processa Pharmaceuticals when it was trading at $2.8594, up $0.8094 (+39.48%), on 641.6K shares traded. It opened the regular session at $3.65 and made several runs past $5, including today’s high of $5.9099, before closing at $5.10, up $3.05 (+148.78%), on trading volume of 73.3M shares traded.
Keep an eye on this one, because it’s trading well in the aftermarket, after hitting a new a 52-week low yesterday, so there may be some shorts taking a beating, but keep the other eye on a potential funding move. Just one man’s opinion, based on no special data.
For more information, visit www.processapharma.com.
We covered Rail Vision’s (NASDAQ:RVSN) EU approval news, last week, when it was at $2.51, but originally thought that it was better as a scalp. We correctly warned that it was outrunning its support, on Tuesday, and today stated that it appeared to be squeezing after it rallied on its recent announcement that its Main Line system successfully obtained formal certifications for critical European Union (EU) railway standards.
Rail Vision hit a 10-month high of $10.35 and closed at $7.58 (+40.11%), on 35.8M shares traded.
Rail Vision is a technology company that is seeking to revolutionize railway safety and the data-related market. The Company has developed cutting-edge, artificial intelligence based, industry-leading technology specifically designed for railways. The Company has developed its railway detection and systems to save lives, increase efficiency, and dramatically reduce expenses for the railway operators. Rail Vision believes that its technology will significantly increase railway safety around the world, while creating significant benefits and adding value to everyone who relies on the train ecosystem: from passengers using trains for transportation to companies that use railways to deliver goods and services. In addition, the company believes that its technology has the potential to advance the revolutionary concept of autonomous trains into a practical reality. For more information, visit https://www.railvision.io/
Have a great evening and we’ll see you tomorrow.
CONTACT:
24/7 Market News
24/7 MARKET NEWS, INC Disclaimer
24/7 Market News (24/7MN) is a third-party publisher and online news dissemination service provider that produces regular sponsored and non-sponsored reports, articles, stock market blogs, and newsletters covering equities listed on the NYSE, NASDAQ, and micro-cap exchanges. 24/7MN holds no investment licenses and is NOT a financial advisory firm, investment adviser, analyst, or broker-dealer and does not undertake any activities that would require such registration. 24/7 MN is not affiliated with any company written about in this release and owns no shares of stock. 24/7MN’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.
The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and based on publicly available information which is believed to be reliable.
Few succeed in the stock market. Don’t trade if you’re not able to devote the necessary time. Earmark your surplus funds that you’re prepared to lose. Assess your risk appetite and set your stops accordingly, and honor your stop losses. Always employ loss limiting strategies. Be prepared to be blindsided by hidden risks, a bad company financing or other move can turn gains into losses.
Learn technical analysis, charting, patterns, and setups. Buying at the bottom and selling at the top is a myth. The middle half of a move is the sweet spot and learn how to exit a winning position, because trying to time the exact top can turn into big losses. Trade small and take advantage of small price move strategies, like scalping.
Remove emotional and psychological biases, and consider that you’re competing against professionals who’re deploying a number of powerful stock market tools. Successful traders make more on their winners than they lose on their losers. Learn how to interpret the ECN/Level 2 data.
The stocks and strategies discussed are simply ideas only and are in no way financial advice or recommendations. The author may or may not at any time be holding securities discussed. The author may or may not enter trades in the stocks mentioned. Some positions in mentioned stocks may already be held or are being adjusted or are simply examples, ideas or discussion topics. You are always trading at your own risk.
Please go to 247marketnews.com or https://247marketnews.com/terms-disclaimer/ for further information.
Connect with 24/7 Market News:
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.